scholarly journals Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.

1997 ◽  
Vol 100 (11) ◽  
pp. 2744-2751 ◽  
Author(s):  
H Wennbo ◽  
M Gebre-Medhin ◽  
A Gritli-Linde ◽  
C Ohlsson ◽  
O G Isaksson ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Transgenic Mice ◽  
Hormone Receptor ◽  
Growth Hormone Receptor ◽  
Prolactin Receptor ◽  
Mammary Tumors

scholarly journals The Role of the Bovine Growth Hormone Receptor and Prolactin Receptor Genes in Milk, Fat and Protein Production in Finnish Ayrshire Dairy Cattle

Genetics ◽  
2006 ◽  
Vol 173 (4) ◽  
pp. 2151-2164 ◽  
Author(s):  
Sirja Viitala ◽  
Joanna Szyda ◽  
Sarah Blott ◽  
Nina Schulman ◽  
Martin Lidauer ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Dairy Cattle ◽  
Hormone Receptor ◽  
Milk Fat ◽  
Protein Production ◽  
Growth Hormone Receptor ◽  
Prolactin Receptor ◽  
Bovine Growth Hormone

scholarly journals Revealing the Mechanistic Details of Growth Hormone Receptor and Prolactin Receptor Interactions on the Cell Membrane

2020 ◽  
Vol 118 (3) ◽  
pp. 94a-95a
Author(s):  
Chen Chen ◽  
Jing Jiang ◽  
Tejeshwar C. Rao ◽  
Stuart J. Frank ◽  
André Leier
Keyword(s):  
Growth Hormone ◽  
Cell Membrane ◽  
Hormone Receptor ◽  
Growth Hormone Receptor ◽  
Prolactin Receptor ◽  
Receptor Interactions

scholarly journals Preparation of a Growth Hormone Receptor/Prolactin Receptor Bispecific Antibody Antagonist Which Exhibited Anti-Cancer Activity

2020 ◽  
Vol 11 ◽  
Author(s):  
Xin Chen ◽  
Di Wu ◽  
Yan Zheng ◽  
Xingxing Liu ◽  
Jianmeng Wang
Keyword(s):  
Breast Cancer ◽  
Growth Hormone ◽  
Cancer Cell ◽  
Hormone Receptor ◽  
Intracellular Signaling ◽  
Growth Hormone Receptor ◽  
Prolactin Receptor ◽  
Dual Function ◽  
Internal Image ◽  
Idiotypic Antibody

Prolactin receptor (PRLR) and growth hormone receptor (GHR) are closely related to the occurrence and development of breast cancer, and breast cancer cell endogenously express GHR, PRLR and GHR-PRLR heterodimer. In this case, the combined use of PRLR or GHR inhibitors may produce better anti-breast cancer potential than PRLR or GHR inhibitors alone. In this case, it is necessary to develop the dual-function GHR/PRLR antagonists with anti-breast cancer potential. For this, we used hybridoma technology to generate an anti-idiotypic antibody (termed H53). We then used various techniques, including competitive ELISA, competitive receptor binding analysis, and indirect immunofluorescence assay to identify H53, and the results show that H53 behaves as a typical internal image anti-idiotypic antibody (Ab2β). Further experiments indicate that H53 is a dual-function inhibitor, which not only inhibited PRLR-mediated intracellular signaling, but also blocked GHR-mediated intracellular signaling in a dose-dependent manner. Furthermore, H53 could inhibit PRL/GH-driven cancer cell proliferation in vivo and in vitro. This study indicates that H53 exhibits potential biological activity against breast tumors, which implies that internal image anti-idiotypic antibodies may be a useful strategy for the development of PRLR/GHR dual-function antagonists for breast cancer therapy.

scholarly journals Expression and Molecular Characterization of the Growth Hormone Receptor in Canine Mammary Tissue and Mammary Tumors

Endocrinology ◽  
1999 ◽  
Vol 140 (12) ◽  
pp. 5907-5914 ◽  
Author(s):  
Evert van Garderen ◽  
Hein J. A. van der Poel ◽  
Joost F. Swennenhuis ◽  
Esther H. J. Wissink ◽  
Gerard R. Rutteman ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Molecular Characterization ◽  
Hormone Receptor ◽  
Growth Hormone Receptor ◽  
Mammary Tumors ◽  
Mammary Tissue
Sign in / Sign up

Export Citation Format

Share Document